PAP
CSTL icon

Persistent Asset Partners’s Castle Biosciences CSTL Stock Holding History

Persistent Asset Partners’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,463
Closed -$95.8K – 365
2025
Q4 		$95.8K Buy
+2,463
New +$79.4K 0.04% 270

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Persistent Asset Partners's CSTL Position: Q1 2026 in Review

Persistent Asset Partners sold out of Castle Biosciences (CSTL) in Q1 2026, closing a stake of 2,463 shares — an estimated $95.8K sold.

Persistent Asset Partners first reported a position in CSTL in Q4 2025 and held it in 1 quarter. The position peaked at $95.8K in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Persistent Asset Partners reported no remaining Castle Biosciences position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 2,463 Castle Biosciences shares in Q1 2026, an estimated $95.8K.
  • Persistent Asset Partners first reported a position in Castle Biosciences in Q4 2025 and held it in 1 quarter.
  • Persistent Asset Partners's Castle Biosciences position peaked at $95.8K in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.